US 12319738
Anti-FGFR2 antibodies in combination with chemotherapy agents in gastric cancer
granted A61KA61K2039/505A61K2039/54
Quick answer
US patent 12319738 (Anti-FGFR2 antibodies in combination with chemotherapy agents in gastric cancer) held by Five Prime Therapeutics, Inc. expires Mon May 29 2045 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Five Prime Therapeutics, Inc.
- Grant date
- Tue Jun 03 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon May 29 2045 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 12
- CPC classes
- A61K, A61K2039/505, A61K2039/54, A61K2039/545, A61K2300/00